Q-omics provides the consensus-scored BCKDHA profile across patient tissues and cancer cell-line models. BCKDHA expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BCKDHA is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, BCKDHA RNA expression shows 19,088 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where BCKDHA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCKDHA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCKDHA survival associations across molecular data types. BCKDHA RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCKDHA RNA expression–survival associations across cancer types. High BCKDHA expression shows unfavorable associations in UVM, but favorable associations in KIRC, HNSC, UCS, ESCA and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BCKDHA RNA expression.
This table summarizes BCKDHA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for BCKDHA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCKDHA shows lower tumor expression in THCA, HNSC, KIRP, KICH, UCEC and LUAD. The THCA box plot shows higher BCKDHA RNA expression in normal versus tumor tissue (log2 FC = −0.577, t-test p < 0.001).
This table shows molecular features associated with BCKDHA in patient tissues and cancer cell lines. In patient samples, BCKDHA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCKDHA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BREAST.
